TPX-100 Peptide Modifies Periarticular Bone Shape in Knee Osteoarthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, particularly knee OA, are limited in effectively addressing joint degeneration and pain, with existing therapies focusing on symptom management rather than disease modification, and there is a need for a method that can delay, arrest, or reverse pathological changes in joint bone shape associated with OA progression.
Innovation Solution
Administration of a formulation containing the TPX-100 peptide, which modifies three-dimensional periarticular bone shape through local injection, delaying or reversing bone area and shape changes, thereby addressing the underlying bone structure changes that contribute to OA progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (NSAIDs, corticosteroids, hyaluronic acid) are used to manage knee OA pain, then pain relief may be achieved temporarily, but they fail to address the underlying bone shape changes and do not modify disease progression
Solution Approach 1:
The patent identifies that subchondral bone changes (sclerosis, cysts, shape alteration) are harmful factors that drive OA progression. The invention converts this understanding into benefit by developing a treatment that specifically targets and modifies these bone changes, thereby stopping the disease progression mechanism at its source rather than merely managing symptoms.
Solution Approach 2:
The patent extracts the specific pathological mechanism of subchondral bone shape change from the overall OA disease process. By isolating this specific mechanism as the primary target for intervention, the treatment can address the root cause of disease progression separately from symptom management, enabling true disease modification.
2Ease of operation
If symptomatic treatment approaches are used to manage knee OA, then pain and function may be temporarily improved, but the pathological bone shape changes continue to progress
Solution Approach 1:
The patent applies preliminary action by targeting subchondral bone changes early in the disease process, before they cause irreversible cartilage loss and joint failure. By intervening at the bone level early in the pathological cascade, the treatment prevents subsequent cartilage degradation and maintains joint structure stability over time.
3Reliability
If invasive surgical procedures are performed to address severe knee OA, then joint function may be restored, but the risk of complications and need for additional surgeries increases
Solution Approach 1:
The patent replaces mechanical surgical intervention with a biochemical/pharmacological approach. Instead of using mechanical tools to physically alter or replace joint structures, the invention uses a therapeutic agent that modifies the biological processes driving bone and cartilage degeneration, thereby avoiding surgical risks and complexities.
Data Source
AI summary
Knee pain caused by osteoarthritis is relieved by modifying the shape change of bone(s) underlying articular cartilage, by a method comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint.